Contact the EPIPEN4SCHOOLS Programs

Phone: 973-845-7600
Fax: 973-718-4328

BioRidge Pharma facilitates the certification and fulfillment
of the EPIPEN4SCHOOLS® orders.
The EPIPEN4SCHOOLS® program helps improve access to epinephrine in the event a person experiences a life-threatening allergic reaction (anaphylaxis) in the school setting.
The program offers qualifying schools*:
  • Four free EPIPEN® (epinephrine injection, USP) or EPIPEN JR® (epinephrine injection, USP) Auto-Injectors in the form of two EPIPEN 2-PAK® cartons, two EPIPEN JR 2-PAK® cartons or one 2-Pak of each kind.
    Note: schools may receive the authorized generic versions of EPIPEN and EPIPEN JR
  • Free replenishment product in the event that the free supply is used to respond to a life-threatening allergic reaction.
  • How to Use an EPIPEN (epinephrine injection, USP) Auto-Injector, containing instructions on how to administer.
  • EPIPEN Trainers, which contain no drug product or needle, to practice administering EPIPEN Auto-Injector.
CLICK HERE to start your order.
Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should receive an intramuscular injection of epinephrine and seek immediate emergency medical care. Carrying an epinephrine auto-injector does not prevent patients from having an anaphylactic reaction; hence, patients must avoid their triggers at all times.
For more information on anaphylaxis or EPIPEN Auto-Injectors, visit

Did you know?

Anaphylaxis can develop and progress quickly, and children and adolescents are among the most at risk. A survey of more than 8,048 schools participating in EPIPEN4SCHOOLS revealed a total of 1,568 anaphylactic events among students and staff during the 2015-2016 school year. Also, the survey found:

  • More than one in four anaphylactic events occurred in the absence of an established or known allergic trigger
  • In 17% of reported anaphylaxis cases, the individual was not treated with epinephrine, the only first-line treatment for anaphylaxis
  • In those events where an epinephrine auto-injector was used, nearly 60% were treated with an EPIPEN Auto-Injector provided by the EPIPEN4SCHOOLS program
* A school will only receive epinephrine auto-injectors in accordance with all applicable laws. A school must submit a valid prescription in order to qualify for this program.